iiinova — where your digital self keeps evolving

Reposted by Sunil Badve

The Lancet Diabetes & Endocrinology @thelancetendo.bsky.social · 09/08/2026

#Semaglutide was effective in decreasing #CKD progression regardless of the administration route or indication (type 2 #diabetes or #obesity), adding to the evidence provided by FLOW in people with type 2 diabetes & CKD www.thelancet.com/journals/lan... #T2D #kidney #CVD #MedSky #RenalSky #CardioSky

Cumulative incidence plots showing time from randomisation to occurrence of first primary kidney composite event (A) and narrower secondary kidney composite event (B). Pooled data from the SELECT, FLOW, and SOUL trials, in the full analysis set. The primary kidney composite included onset of persistent ≥50% reduction in eGFR, kidney failure (persistent eGFR <15 mL/min per 1·73 m2 or initiation of kidney replacement therapy), kidney-related death, or cardiovascular-related death. Narrower secondary kidney composite included the above criteria, excluding cardiovascular-related death. eGFR=estimated glomerular filtration rate. HR=hazard ratio. IR=incidence rate (number of events per 100 years of observation).

0104

Sunil Badve @sunilbadve.bsky.social · 08/08/2026

Read our latest pre-specified pooled analysis of SELECT SOUL and FLOW assessing the effect of semaglutide on kidney outcomes

030

Reposted by Sunil Badve

JAMA @jama.com · 04/06/2026

📊 Research Summary: In advanced chronic #kidney #disease (#CKD), low-dose rivaroxaban did not reduce #cardiovascular events and increased major bleeding rates versus placebo. #ERA26 ja.ma/4uPCpnZ

JAMA Research Summary: Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease. Graphics show 727 patients took Rivaroxaban (22.6% primary outcome) and 731 took Placebo (20.7% primary outcome). Rivaroxaban did not reduce cardiovascular events and increased major bleeding (8.8% vs 6.0%).

051

Reposted by Sunil Badve

JAMA @jama.com · 04/06/2026

💬 Editorial: In advanced #CKD, low-dose rivaroxaban did not reduce cardiovascular events and increased major bleeding risk. The TRACK trial highlights the necessity of disease-specific evidence before adopting preventative therapies. #ERA26 ja.ma/4o8bwcp

JAMA editorial titled 'Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease High Risk, but No Reward?' by Nisha Bansal & Wolfgang Winkelmayer. Published online June 4, 2026, the page discusses cardiovascular disease in CKD patients.

061

Reposted by Sunil Badve

JAMA @jama.com · 04/06/2026

Among adults with advanced chronic #kidney #disease (#CKD) stage 4 or 5 or on #dialysis, low-dose rivaroxaban did not lower #cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group. #ERA26 ja.ma/43KWboD

JAMA study: Question: Does low-dose rivaroxaban reduce cardiovascular events in advanced CKD vs. placebo? Conclusion: No, but increased major bleeding. 1458 patients analyzed. Findings: Rivaroxaban 22.6% vs. Placebo 20.7% for events; not significant. Major bleeding: Rivaroxaban 8.8%, Placebo 6.0%.

053

Reposted by Sunil Badve

Eric Topol @erictopol.bsky.social · 15/01/2026

A 5★ new review of the GLP-1 drugs, what they have achieved, and where the field is headed with so many new molecules and combinations @thelancet.com thelancet.com/journals/lan...

114630

Reposted by Sunil Badve

Josh Waitzman @jwaitz.bsky.social · 13/10/2025

Loved watching @kidneyrebel.bsky.social grand rounds at @nu-nephrology.bsky.social!! Thank you for the PKD mega blocks shout out #nephjc (1), happy to be at the right overlap in my Venn diagram (2), and trying to build toward a medical specialty in a hill (3) www.youtube.com/watch?v=RlTC...

154

Sunil Badve @sunilbadve.bsky.social · 19/08/2025

Huge congratulations Mike and Lonnie.

030

Reposted by Sunil Badve

Internal Medicine Journal @the-imj.bsky.social · 13/06/2025

IMJ June 2025 #OpenAccess Editor's choice (original article): Smoking and kidney transplantation wait listing bit.ly/4kFslsJ @theracp.bsky.social @sunilbadve.bsky.social

022

Reposted by Sunil Badve

Internal Medicine Journal @the-imj.bsky.social · 15/06/2025

IMJ June 2025 #FreeAccess Editorial: Smokers and kidney transplantation assessment: a question of risk or equity? bit.ly/3FUCH8Q @theracp.bsky.social @sunilbadve.bsky.social

022

Sunil Badve @sunilbadve.bsky.social · 15/05/2025

Save the date for Kidney Supportive Care Masterclass 2025 and Serious Illness Conversations Workshop. Open to nephrologists, nephrology trainees and nurse practitioners. Separate registrations for the Masterclass (forms.office.com/r/L90B6DrscS) and the Workshop (email in the image).

151

Reposted by Sunil Badve

Brendon Neuen @brendonneuen.bsky.social · 30/01/2025

📢 New Systematic Review & Meta-Analysis in @kireports.bsky.social 📢 We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵 www.kireports.org/article/S246...

1198

Reposted by Sunil Badve

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 13/12/2024

The UKKA AKI report is out, h/t @beckybonfield.bsky.social @ukkidney.org www.ukkidney.org/sites/defaul... (PDF) Incl. - Don’t call RAASi nephrotoxic - Don’t delay contrast imaging - Sick day rules are mostly 🐴 💩

23920

Reposted by Sunil Badve

Brendon Neuen @brendonneuen.bsky.social · 27/11/2024

In people with T2D, effects of GLP1-RA on CV, kidney & mortality outcomes are consistent irrespective of SGLT2i Our meta-analysis of the 3 GLP1RA diabetes clinical outcome trials with the largest prevalent use of SGLT2i in @ahajournals.bsky.social Circulation www.ahajournals.org/doi/10.1161/...

02413

Reposted by Sunil Badve

Brendon Neuen @brendonneuen.bsky.social · 26/11/2024

Clear ⏬ with GLP-1RA by ~15% for all clinical outcomes including: Kidney failure ✅ Major CV events ✅ Heart failure ✅ CV death ✅ All-cause death ✅ Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes Now in Lancet D&E: www.thelancet.com/journals/lan...

24921

Sunil Badve @sunilbadve.bsky.social · 26/11/2024

Sharing the free access link here (for 50 days only) authors.elsevier.com/a/1k9u77tNuc...

authors.elsevier.com

0116

Reposted by Sunil Badve

Thorn-Seshold Lab @thornsesholdlab.bsky.social · 22/11/2024

Wishing the Elsevier editors who desk-accepted this all the best for their next career moves. doi.org/10.1016/j.ij...

1021492505

Reposted by Sunil Badve

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 15/11/2024

Good morning! Nov 15 AM update: The 3rd Nephrology pack is well known its way: go.bsky.app/2yLiYN4 Second pack go.bsky.app/N27Kzri First pack: go.bsky.app/H4td28C Hypertension Nerds go.bsky.app/KBLojr Kidney/HT Journals go.bsky.app/2BG7wKr Please reply or DM me to be added!

285519